{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:28:32Z","timestamp":1789738112475,"version":"4.0.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/dad.0000000000000018","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T13:05:52Z","timestamp":1403355952000},"page":"557-561","source":"Crossref","is-referenced-by-count":17,"title":["Histological Features Associated With Vemurafenib-Induced Skin Toxicities"],"prefix":"10.1097","volume":"36","author":[{"given":"Jonathan L.","family":"Curry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Y.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jen","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres-Cabala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210202","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/ijc.22144","article-title":"Raf kinases: oncogenesis and drug discovery.","volume":"119","author":"Schreck","year":"2006","journal-title":"Int J Cancer"},{"key":"R2-2-20210202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":". Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R3-2-20210202","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/carcin\/bgh049","article-title":". Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.","volume":"25","author":"Fransen","year":"2004","journal-title":"Carcinogenesis"},{"key":"R4-2-20210202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0463.2005.apm1130108.x","article-title":". Mutational analysis of the ARAF gene in human cancers.","volume":"113","author":"Lee","year":"2005","journal-title":"APMIS"},{"key":"R5-2-20210202","doi-asserted-by":"crossref","first-page":"9719","DOI":"10.1158\/0008-5472.CAN-05-1683","article-title":". Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.","volume":"65","author":"Emuss","year":"2005","journal-title":"Cancer Res"},{"key":"R6-2-20210202","first-page":"756","article-title":". Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.","volume":"63","author":"Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"key":"R7-2-20210202","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":". Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-2-20210202","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":". Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"R10-2-20210202","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors.","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"R11-2-20210202","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":". Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R12-2-20210202","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":". Analysis of dermatologic events in vemurafenib-treated patients with melanoma.","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"R13-2-20210202","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":". Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"R14-2-20210202","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":". Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.","volume":"18","author":"Arnault","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R15-2-20210202","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":". Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"R16-2-20210202","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamadermatol.2013.2023","article-title":". Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.","volume":"149","author":"Falchook","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R17-2-20210202","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1074-5521(99)80088-X","article-title":". Paradoxical activation of Raf by a novel Raf inhibitor.","volume":"6","author":"Hall-Jackson","year":"1999","journal-title":"Chem Biol"},{"key":"R18-2-20210202","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":". RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"R19-2-20210202","first-page":"329","article-title":"Rosen N, et al..","volume":"30","author":"Lacouture","year":"2012","journal-title":"Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern J Clin Oncol"},{"key":"R20-2-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":". RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"R21-2-20210202","doi-asserted-by":"crossref","first-page":"e58721","DOI":"10.1371\/journal.pone.0058721","article-title":". RASopathic skin eruptions during vemurafenib therapy.","volume":"8","author":"Rinderknecht","year":"2013","journal-title":"PloS One"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000000018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:56:46Z","timestamp":1620950206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201407000-00002"}},"subtitle":["Examination of 141 Cutaneous Lesions Biopsied During Therapy"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000018","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}